Clinical Trial Update: The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the rGBM [Phase 1]

View source ↗

Summary

Clinical trial update on the safety and efficacy of SNC-109 CAR-T Cells Therapy for recurrent glioblastoma multiforme, currently in Phase 1 and enrolling by inv…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• SNC-109 CAR-T Cells Therapy (SNC-109 CAR-T)

Snippet

Sponsor: Shanghai Simnova Biotechnology Co.,Ltd. | Conditions: Recurrent Glioblastoma Multiforme (GBM) | Phase 1 | Status: ENROLLING_BY_INVITATION